Latest Novartis Ag (NVS) Headlines goBalto, Inc
Post# of 54
goBalto, Inc. Releases New Enhancements to Address Continued Market Momentum
PR Newswire - Thu Mar 13, 1:10PM CDT
goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today updates to its signature software platform. Key enhancements include additional global configuration support and new integration capabilities for smooth enterprise implementation.
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
5 Stock Charts Screaming 'Buy' in March
at The Street - Thu Mar 13, 8:43AM CDT
Here's a look at five high-volume stocks to trade.
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Novartis Bexsero(R)a- 1/4 Meningitis B Vaccine Receives Clinical Recommendation for Use in Infants and Adolescents in Australia
PR Newswire Europe - Thu Mar 13, 2:32AM CDT
FRIMLEY, England, March 13, 2014 /PRNewswire/ --
Novartis Bexsero(R) meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia
Thomson Reuters ONE - Thu Mar 13, 1:16AM CDT
Novartis International AG / Novartis Bexsero(R) meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Can Valeant Continue This Growth?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:00PM CDT
Canada's Valeant Pharmaceuticals is a good example of what can be done when a company chooses to go its own way and zig while others zag. In an industry that had becoming increasingly skittish about mergers and acquisitions as a growth driver,...
Research and Markets: Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
Business Wire - Wed Mar 12, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r75h94/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering.
Research and Markets: Global Smart Pill Technology Market 2012-2016 with Novartis AG, Olympus Medical Corp. and Philips Healthcare Dominating
Business Wire - Wed Mar 12, 12:31PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wl6wqg/global_smart_pill) has announced the addition of the "Global Smart Pill Technology Market 2012 2016" report to their offering.
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Smart Pill Technology Market 2012-2016 with Novartis AG, Olympus Medical Corp. and Philips Healthcare Dominating
M2 - Wed Mar 12, 11:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ckrgpq/global_smart_pill) has announced the addition of the "Global Smart Pill Technology Market 2012 2016" report to their offering. The analysts forecast the Global Smart Pill Technology market 2012-2016 to grow at a CAGR of 6.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is increasing prevalence of gastro-intestinal (GI) disorders. The Global Smart Pill Technology market has also been witnessing the trend of growing popularity of dental tourism. However, limited availability of smart pill technology devices could pose a challenge to the growth of this market. Key vendors dominating this market space Given Imaging Ltd., Novartis AG, Olympus Medical Corp., and Philips Healthcare Commenting on the report, an analyst from the Healthcare team said:'The prevalence of GI diseases such as colorectal cancer and esophagitis has increased over time, leading to the need for screening procedures as many such diseases can be cured when detected early. It is estimated that colorectal cancer accounts for more than 10 percent of the total number of cancer cases worldwide. The increased need for screening for various GI diseases increases the scope for the usage of endoscopy devices. Moreover, since many healthcare institutions prefer endoscopes and smart pills for screening procedures for GI disorders, the growth of the market is expected to increase during the forecast period.' According to the report, one of the key drivers in this market is the significant rise in the number of people suffering from GI disorders, which is mainly a result of changing lifestyles and food habits. Consequently, there has been an increase in the diagnosis and treatment of GI disorders. The report also includes a discussion on the other prominent vendors in this market,such as Philips Healthcare, Medtronic Inc., and Medimetrics. For more information visit http://www.researchandmarkets.com/research/ck...smart_pill About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
M2 - Wed Mar 12, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k4v44m/hiv_vaccine) has announced the addition of the "HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" report to their offering. Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV. Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully. HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries. Key Topics Covered: 1. Introduction to HIV Vaccine & Mechanism 2. HIV Vaccine: Prevention & Cure 3. Why Need For HIV Vaccines? 4. Global HIV Vaccine Market Outlook 5. Research & Development Funding Scenario for HIV Vaccine 6. HIV Vaccine Market Dynamics 7. FDA Regulatory Framework for Development of HIV Vaccine 8. HIV Vaccine Clinical Trial by Phase & Country 9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country 10. Competitive Landscape - Antigen Express - Bionor Pharma - FIT Biotech - GenVec - GeoVax - Glaxo Smithkline - Immune Response BioPharma - Inovio Pharmaceuticals - Novartis - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/k4...iv_vaccine
PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:10AM CDT
PDL BioPharma announced that it expects to receive revenues of roughly $133 million in the first quarter of 2014.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
M2 - Wed Mar 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5vwnh/pharmapoint) has announced the addition of the "PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update" report to their offering. New Serogroup B Vaccines to Claim Half of Meningococcal Vaccines Market by 2022 Upcoming and long-awaited market entries for Novartis' Bexsero and Pfizer's MnB rLP2086 will prompt significant growth in the meningococcal vaccines market over the next decade, states research and consulting firm The authors. According to the report, the arrival of these eagerly awaited serogroup B vaccine will drive combined revenue for meningococcal vaccines across the US, France, Germany, Italy, Spain, the UK, Japan, Australia, and Brazil, from $1.2bn in 2012 to just over $2bn in 2022, increasing by 65%. Novartis' Bexsero, which received approval from the European Medicines Agency (EMA) in January, is forecast to produce global sales of over $330m by 2022, while Pfizer's MnB rLP2086, which is expected to launch in the US in 2017 and in the EU the following year, is forecast to reach total revenue of over $700m by 2022. Combined, these two products are expected to dominate the meningococcal vaccines market by the end of the forecast period, accounting for a 52% share. According to Dr Christopher Pace, The authors's analyst covering infectious disease: Despite legitimate concerns from policymakers regarding the cost-effectiveness of adding an additional vaccine to already-crowded immunization schedules, serogroup B incorporation will be well received by prescribers and patients, alike. Novartis and Pfizer are expected to dominate this segment of the market, with their respective products responsible for the majority of global market growth over the next decade. The authors's report states that the cost-effectiveness of meningococcal vaccines is a universal barrier to global market growth, with the inherently high cost per dose and relatively low incidence rates of meningococcal disease leading to increased government skepticism in the face of new vaccine launches and immunization program expansions. Dr Pace believes that while these concerns are not expected to significantly prohibit the adoption of serogroup B vaccines, such as Bexsero and MnB rLP2086, government assessment of cost-effectiveness is considered to be a primary determinant of a vaccine's commercial success. Key Topics Covered - Table of Contents - Introduction - Disease Overview - Epidemiology - Disease Management - Competitive Assessment - Opportunity and Unmet Need - Pipeline Assessment - Current and Future Players - Market Outlook - Appendix Companies Mentioned - Baxter - GlaxoSmithKline - Novartis - Nuron Biotech - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/p5...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Codexis Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:04PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Research and Markets: Investigation Report on China's Imatinib Market, 2009-2018
Business Wire - Tue Mar 11, 11:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2dlz6n/investigation) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering.
Investigation Report on China's Imatinib Market, 2009-2018
M2 - Tue Mar 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vs6ngt/investigation) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering. Imatinib is originally developed by Novartis with the trade name ""Gleevec"". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after a-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its revolutionary treatment, imatinib prolongs 85% to 90% CML patients' life by 10 years. With much less side effects, imatinib is significantly safer than interferon. As a result, it became a first-line drug in CML treatment soon. In 2002 imatinib gained accelerated approval from FDA to be the first-line drug in advanced or metastatic gastrointestinal stromal tumors (GIST) treatment. As a first-line drug in clinical treatment, the sales revenue of imatinib exceeded USD 1 billion in 2003 and it is still increasing rapidly. Imatinib acquired its first indication approval in 2001 and has since then acquired 10 indication approvals. Increasing number of indications is also one of the main factors making imatinib a blockbuster drug. Imatinib was approved to China in 2002 to treat CML and GIST. Its market size keeps increasing after its launch. According to CRI's investigation on sample hospital market, the CAGR of its sales revenue exceeded 40% from 2005 to 2012. It is estimated that growth of original drugs will slow down because of launched generic drugs. As an orphan drug approved to the market, imatinib becomes a blockbuster drug mainly due to the successful marketing strategy. Considered as a specific drug to treat rare diseases (CML and GIST), Gleevec makes a marketing strategy to launch drug donation charity program through negotiation with medicare institutes. The program allows patients to take the drug for free after the donation so as to increase patients' dependence on the drug. This gesture has not only solved patients' problems but also brought excellent reputation for Gleevec, making its global sales revenue surge. Key Topics Covered: 1 Relevant Concepts of Imatinib 2 Market Overview of Imatinib in China, 2010-2013 3 Investigation on Sales Value of Imatinib in China, 2010-2013 4 Investigation on Market Share of Major Imatinib Manufacturers in China, 2010-2013 5 Investigation on Market Size of Imatinib by Dosage Form in China, 2010-2013 6 Reference Price of Imatinib Produced by Different Enterprises in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Imatinib Market, 2009-2014 8 Prospect of China Imatinib Market, 2014-2018 Companies Mentioned - Novartis - Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - Hansoh Pharmaceutical For more information visit http://www.researchandmarkets.com/research/vs...estigation